EasyNAT GBS Assay
Ongoing Challanges
The CDC and ACOG recommend universal Group B *Streptococcus* (GBS) screening for all pregnant women between 35 and 37 weeks of gestation.
Intrapartum antibiotic prophylaxis (IAP) is highly effective, but managing the 70-90% of women who test negative, ensuring appropriate care without unnecessary antibiotics, is a challenge.
The WHO advocates for widespread screening to reduce neonatal morbidity and mortality.
Product Overview
This assay is an automated, in vitro nucleic acid amplification test for the qualitative detection of Group B *Streptococcus* (GBS) DNA in vaginal swabs from antepartum and intrapartum women.
Results obtained within 48 minutes
Designed to provide an accurate LOD: 200 copies/mL
Moderately complex testing with less than 1 minute of hands-on time
Provides swift results for patients with unknown GBS status
Dramatically improves the patient experience and reduces infection risk, assisting doctors in providing practical treatment guidance.
Clinical Value
Dramatically improves the patient experience.
Reduces infection risk in antepartum and intrapartum women.
Lowers the laboratory’s burden for antenatal screening.
